fda import alert semaglutide tirzepatide green list SFDA updates guidelines for pharmaceutical variation requirements | Jameel M. Althiyabi posted on the topic September 8, 2025: FDA launches

The primary endpoint was the mean change in HbA1c from baseline to week 52 for tirzepatide relative to insulin lispro ( 4.7 SURPASS J-mono trial in Japan In Japan, the SURPASS J-mono trial enrolled 636 Japanese adults with type 2 diabetes (age 20 years) who discontinued oral monotherapy or were treatment-naive due to hyperglycemia ( 4.8 SURPASS J-combo trial in Japan The SURPASS J-combo trial included 443 Japanese adults with type 2 diabetes (age 20 years, BMI 23 kg/m 2 , inadequately controlled HbA1c), who received tirzepatide 5 mg, 10 mg, 15 mg in addition to oral antidiabetic drugs for 3 months

Muscle is metabolically expensive tissue it burns calories at rest, which is a large part of what determines resting metabolic rate

When you start any medication with a long half-life, the first several doses are building toward a stable baseline

Patients should avoid combining tesofensine with other medications affecting serotonin, norepinephrine, or dopamine levels, as this could increase the risk of side effects

This dual mechanism is what separates tirzepatide from single-receptor drugs like semaglutide, which only targets GLP-1

This dual action suppresses appetite, slows gastric emptying, improves insulin sensitivity, and promotes significant weight loss